Aciont To Present Phase 1/2 Clinical Trial Top Line Data at The 9th Annual Ophthalmology Innovation Summit at AAO

Salt Lake City, UT – November 8, 2017 – Aciont Inc. announced today that John Higuchi, its CEO, will be presenting topline data of Aciont's lead product, DSP-Visulex in a phase 1/2 clinical trial in the treatment of noninfectious, anterior uveitis (DSPV-201).

"I am excited to share our first in human study results of DSP-Visulex from both safety and efficacy standpoints to this specialized audience of business executives, physicians and investors in the fields of ophthalmology," Higuchi said.

Dr. Kongnara Papangkorn, VP of Product Development, Aciont's key study investigator for the clinical trial, noted that "4 or 5 doses of DSP-Visulex provided the same efficacy results to the standard of care, prednisolone acetate with 112 drops, without any signs of IOP elevation." Papangkorn added that, "The feedback about the ease of use of our approach from our ophthalmologists has been favorable and the aforementioned findings of efficacy with improved safety and tolerance are significant."

This presentation will be on Thursday, November 9th during at Company Showcase, Session 1 from 8.40 AM to 9.43 AM. The OIS@AAO meeting will be at Hyatt Regency New Orleans and the agenda of the meeting can be found at the OIS website: https://ois.net/ois-aao-2017/agenda/

DSP-Visulex is a noninvasive drug delivery system of dexamethasone sodium phosphate (DSP). It utilizes a combination of a proprietary high concentration DSP solution and Visulex-P drug applicator technology to enable a simple administration of DSP to treat inflammation conditions of both anterior and posterior eye tissues.

DSPV-201 is a multicenter, randomized, parallel group, double-masked, active-controlled study of DSP-Visulex in noninfectious anterior uveitis patients. Weekly DSP-Visulex therapy was compared to daily prednisolone acetate 1% eye drops. The study was supported by two phase 2 NEI SBIRs, reference by Grant R44EY014772, and the clinical study is registered at clinicaltrials.gov under identifier NCT02309385.